Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133.

Article  PubMed  PubMed Central  Google Scholar 

Morris LGT, Sikora AG, Tosteson TD, Davies L. The Increasing Incidence of Thyroid Cancer: The Influence of Access to Care. Thyroid. 2013;23:885–91.

Article  PubMed  PubMed Central  Google Scholar 

Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk Factors. J Cancer Epidemiol. 2013;2013: 965212.

Article  PubMed  PubMed Central  Google Scholar 

Schmidbauer B, Menhart K, Hellwig D, Grosse J. Differentiated Thyroid Cancer—Treatment: State of the Art. Int J Mol Sci. 2017;18:1292.

Article  PubMed  PubMed Central  Google Scholar 

Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, et al. Delayed Risk Stratification, to Include the Response to Initial Treatment (Surgery and Radioiodine Ablation), Has Better Outcome Predictivity in Differentiated Thyroid Cancer Patients. Eur J Endocrinol. 2011;165:441–6.

Article  CAS  PubMed  Google Scholar 

Dueren C, Dietlein M, Luster M, Plenzig F, Steinke R, Grimm J, et al. The Use of Thyrogen in the Treatment of Differentiated Thyroid Carcinoma: An Intraindividual Comparison of Clinical Effects and Implications of Daily Life. Exp Clin Endocrinol Diabetes. 2010;118:513–9.

Article  CAS  PubMed  Google Scholar 

Hong CM, Lee WK, Jeong SY, Lee SW, Ahn BC, Lee J. Superiority of Delayed Risk Stratification in Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Ablation. Nucl Med Commun. 2014;35:1119–26.

Article  CAS  PubMed  Google Scholar 

Malandrino P, Tumino D, Russo M, Marescalco S, Fulco RA, Frasca F. Surveillance of Patients with Differentiated Thyroid Cancer and Indeterminate Response: A Longitudinal Study on Basal Thyroglobulin Trend. J Endocrinol Invest. 2019;42:1223–30.

Article  CAS  PubMed  Google Scholar 

Momesso DP, Vaisman F, Yang SP, Bulzico DA, Corbo R, Vaisman M, et al. Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine. J Clin Endocrinol Metab. 2016;101:2692–700.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moreno I, Hirsch D, Duskin-Bitan H, Dicker-Cohen T, Shimon I, Robenshtok E. Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required? Thyroid. 2020;30:863–70.

Article  CAS  PubMed  Google Scholar 

Mukhtar N, Aljamei H, Aljomaiah A, Moria Y, Alzahrani AS. Natural Course of the American Thyroid Association Response to Therapy Statuses (Dynamic Risk Stratification) in Differentiated Thyroid Cancer. Eur Thyroid J. 2021;10:198–207.

Article  PubMed  Google Scholar 

Pitoia F, Jerkovich F. Dynamic Risk Assessment in Patients with Differentiated Thyroid Cancer. Endocr Relat Cancer. 2019;26:R553–66.

Article  CAS  PubMed  Google Scholar 

Robbins RJ, Srivastava S, Shaha A, Ghossein R, Larson SM, Fleisher M, et al. Factors Influencing the Basal and Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin in Patients with Metastatic Thyroid Carcinoma. J Clin Endocrinol Metab. 2004;89:6010–6.

Article  CAS  PubMed  Google Scholar 

Sunny S, Hephzibah J, Mathew D, Bondu J, Shanthly N, Oommen R. Stimulated Serum Thyroglobulin Levels Versus Unstimulated Serum Thyroglobulin in the Follow-Up of Patients with Papillary Thyroid Carcinoma. World J Nucl Med. 2018;17:41–5.

Article  PubMed  PubMed Central  Google Scholar 

Szujo S, Bajnok L, Bodis B, Nagy Z, Nemes O, Rucz K, et al. The Prognostic Role of Postablative Non-Stimulated Thyroglobulin in Differentiated Thyroid Cancer. Cancers. 2021;13:310.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jammah AA, Masood A, Akkielah LA, Alhaddad S, Alhaddad MA, Alharbi M, et al. Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients’ Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial. Front Endocrinol (Lausanne). 2020;11: 603432.

Article  PubMed  Google Scholar 

Kwon SY, Lee SW, Kong EJ, Kim K, Kim BI, Kim J, et al. Clinicopathologic Risk Factors of Radioactive Iodine Therapy Based on Response Assessment in Patients with Differentiated Thyroid Cancer: A Multicenter Retrospective Cohort Study. Eur J Nucl Med Mol Imaging. 2020;47:561–71.

Article  CAS  PubMed  Google Scholar 

Grewal RK, Ho A, Schöder H. Novel Approaches to Thyroid Cancer Treatment and Response Assessment. Semin Nucl Med. 2016;46:109–18.

Article  PubMed  PubMed Central  Google Scholar 

Kloos RT. Thyroid Cancer Recurrence in Patients Clinically Free of Disease with Undetectable or Very Low Serum Thyroglobulin Values. J Clin Endocrinol Metab. 2010;95:5241–8.

Article  CAS  PubMed  Google Scholar 

Vaisman F, Momesso D, Bulzico DA, Pessoa CHCN, Dias F, Corbo R, et al. Spontaneous Remission in Thyroid Cancer Patients After Biochemical Incomplete Response to Initial Therapy. Clin Endocrinol (Oxf). 2012;77:132–8.

Article  CAS  PubMed  Google Scholar 

Robenshtok E, Grewal RK, Fish S, Sabra M, Tuttle RM. A Low Postoperative Nonstimulated Serum Thyroglobulin Level Does Not Exclude the Presence of Radioactive Iodine Avid Metastatic Foci in Intermediate-Risk Differentiated Thyroid Cancer Patients. Thyroid. 2013;23:436–42.

Article  CAS  PubMed  Google Scholar